Perlecan/HSPG2 Antibody (Rat mAb) [E7K4]

CatNo: F2136

    Application: Reactivity:

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    Application
    WB, IP, IHC, IF
    Source
    Rat Monoclonal Antibody
    Reactivity
    Human, Rat, Mouse, Cow, Fish, Pig
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW
    469 kDa

    Datasheet & SDS

    生物学的記述

    Specificity
    Perlecan/HSPG2 Antibody (Rat mAb) [E7K4] detects endogenous levels of total Perlecan/HSPG2 protein.
    Clone
    E7K4
    Synonym(s)
    Basement membrane-specific heparan sulfate proteoglycan core protein, HSPG, Perlecan, PLC, HSPG2
    Background
    Perlecan, encoded by HSPG2, is a large modular heparan sulfate proteoglycan built from domains homologous to laminin, the LDL receptor, and neural cell adhesion molecules, reflecting its evolutionary assembly from diverse matrix-binding motifs into a single multifunctional scaffold. This modular architecture allows perlecan to serve simultaneously as a structural component of basement membranes and as a reservoir that sequesters growth factors through its heparan sulfate side chains, controlling their local availability at the cell surface. Perlecan directly binds vascular endothelial growth factor and promotes activation of VEGF receptor 2 on endothelial cells, and this receptor engagement is required for vascular invasion into cartilage during endochondral bone formation, with perlecan supplied from the cartilage matrix itself rather than from the endothelial cells being the critical source. Perlecan signaling converges on the master metabolic regulators AMPK and mTOR through this same VEGFR2 interaction, linking matrix-anchored growth factor presentation to intracellular autophagy control. Proteolytic release of the C-terminal fragment endorepellin generates a distinct signaling entity that engages overlapping receptor and downstream pathway components to restrain angiogenesis, in part by promoting autophagy in endothelial cells, creating a built-in counterbalance to the pro-angiogenic activity of the intact proteoglycan. HSPG2 transcription is responsive to TGF-beta signaling through direct nuclear factor-1 binding at its promoter, is suppressed by interferon-gamma, and is activated by NF-κB in desmoplastic tumor stroma, positioning perlecan as an early-response gene whose expression shifts rapidly with the surrounding signaling environment. Loss-of-function mutations in HSPG2 disrupt basement membrane stability, cartilage matrix organization, and vascular integrity, and are associated with skeletal dysplasias including Schwartz-Jampel syndrome, while altered perlecan or endorepellin balance in tumor stroma influences angiogenesis and tumor progression.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください